Articles related to GENETIC TESTING/MUTATIONS

In the CodeBreaK 100 study, a lower 240 mg dose of sotorasib demonstrated similar efficacy to the FDA-approved 960 mg dose in treating KRAS G12C–mutated NSCLC, with potentially fewer severe adverse events.

This study highlights repotrectinib’s remarkable efficacy in ROS1 fusion–positive NSCLC, demonstrating a notable response even in patients with the challenging ROS1 G2032R mutation, and presents a new potential standard in targeted lung cancer therapy.

The recent phase 3 trial has demonstrated that the combination of the KRAS G12C inhibitor, sotorasib, with the EGFR inhibitor, panitumumab, can lead to longer progression-free survival in patients with chemorefractory metastatic colorectal cancer.

With an estimated 30% to 40% of unexplained epilepsy cases having a genetic etiology, the newest tools offer the potential for timely, accurate diagnoses, resulting in personalized care that can improve outcomes and enhance quality of life.

The recent data breach at 23andMe, which resulted in the theft of millions of data points from specific users, highlights the urgent need for robust security measures in genetic testing companies.

Discover how the FDA-approved Invitae’s Common Hereditary Cancers Panel can enhance your approach to early cancer detection and personalized treatment planning.